22,085 Shares in Illumina, Inc. $ILMN Acquired by Kerrisdale Advisers LLC

Key Points

• Kerrisdale Advisers acquired 22,085 Illumina shares worth approximately $3.9 million, while institutional investors collectively own 89.42% of the company.
• Illumina reported strong quarterly results, with revenue rising 9.4% year over year to $1.16 billion and EPS of $1.31, beating estimates and prompting higher full-year guidance.
• Although several analysts raised their price targets, the stock’s average target remains $188.40 versus a recent price of $215.59; substantial insider selling and an elevated valuation could weigh on investor sentiment.

Kerrisdale Advisers LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,085 shares of the life sciences company's stock, valued at approximately $3,883,000. Illumina accounts for approximately 1.0% of Kerrisdale Advisers LLC's investment portfolio, making the stock its 20th biggest holding.

A number of other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Illumina during the second quarter worth $3,374,423,000. Primecap Management Co. CA bought a new stake in Illumina in the 2nd quarter valued at $617,981,000. Jupiter Topco LLC purchased a new stake in Illumina in the 2nd quarter worth $358,652,000. WCM Investment Management LLC lifted its stake in Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Illumina in the 2nd quarter worth $293,846,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ILMN. Wall Street Zen raised Illumina from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Zacks Research raised Illumina from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 3rd. Piper Sandler restated an "overweight" rating and set a $225.00 price target (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. JPMorgan Chase & Co. lifted their price objective on Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Finally, Guggenheim upped their price objective on Illumina from $200.00 to $226.00 and gave the stock a "buy" rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $188.40.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $215.59 on Monday. The firm's 50-day moving average price is $194.05 and its 200-day moving average price is $155.87. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $32.55 billion, a price-to-earnings ratio of 40.22, a P/E/G ratio of 3.03 and a beta of 1.44. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the business posted $1.19 earnings per share. The firm's revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares of the company's stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,799,688 shares of company stock worth $379,517,231. 2.90% of the stock is currently owned by company insiders.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source